{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:50:59Z","timestamp":1778802659347,"version":"3.51.4"},"reference-count":101,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.cld.2023.01.016","type":"journal-article","created":{"date-parts":[[2023,2,26]],"date-time":"2023-02-26T15:17:03Z","timestamp":1677424623000},"page":"535-551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Research Priorities for Precision Medicine in NAFLD"],"prefix":"10.1016","volume":"27","author":[{"given":"Paula","family":"Iruzubieta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramon","family":"Bataller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Teresa","family":"Arias-Loste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0499-4191","authenticated-orcid":false,"given":"Marco","family":"Arrese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Calleja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graciela","family":"Castro-Narro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Cusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Luz","family":"Mart\u00ednez-Chantar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5528-1143","authenticated-orcid":false,"given":"Antonio","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E.","family":"Rinella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Romero-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shira","family":"Zelber-Sagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey V.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cld.2023.01.016_bib1","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2023.01.016_bib2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eprac.2021.12.010","article-title":"Fatty liver through the ages: nonalcoholic steatohepatitis","volume":"28","author":"Younossi","year":"2022","journal-title":"Endocr Pract"},{"issue":"9","key":"10.1016\/j.cld.2023.01.016_bib3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2023.01.016_bib4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2023.01.016_bib5","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2006.06.013","article-title":"Hepatic histology in obese patients undergoing bariatric surgery","volume":"45","author":"Machado","year":"2006","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2023.01.016_bib6","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2023.01.016_bib7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2023.01.016_bib8","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41575-021-00477-7","article-title":"Defining comprehensive models of care for NAFLD","volume":"18","author":"Lazarus","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2023.01.016_bib9","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2021.10.025","article-title":"The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge?","volume":"76","author":"Lazarus","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2023.01.016_bib10","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S2468-1253(22)00008-5","article-title":"The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas","volume":"7","author":"D\u00edaz","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2023.01.016_bib12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/liv.13682","article-title":"Liver diseases: a major, neglected global public health problem requiring urgent actions and large-scale screening","volume":"38","author":"Marcellin","year":"2018","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.cld.2023.01.016_bib13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/hep.32163","article-title":"Population screening for liver fibrosis: toward early diagnosis and intervention for chronic liver diseases","volume":"75","author":"Gin\u00e8s","year":"2022","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.cld.2023.01.016_bib14","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.cgh.2017.12.048","article-title":"High prevalence of liver fibrosis among European adults with unknown liver disease: a population-based study","volume":"16","author":"Caballer\u00eda","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2023.01.016_bib15","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/ueg2.12109","article-title":"High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort","volume":"9","author":"Llop","year":"2021","journal-title":"United Eur Gastroenterol J"},{"issue":"3","key":"10.1016\/j.cld.2023.01.016_bib16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","author":"Berzigotti","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.01.016_bib18","doi-asserted-by":"crossref","first-page":"100151","DOI":"10.1016\/j.lana.2021.100151","article-title":"Cirrhosis etiology trends in developing countries: transition from infectious to metabolic conditions. Report from a multicentric cohort in central Mexico","volume":"7","author":"Gonzalez-Chagolla","year":"2022","journal-title":"Lancet Reg Health-Americas"},{"issue":"3","key":"10.1016\/j.cld.2023.01.016_bib19","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.gastha.2021.12.011","article-title":"Prevalence of metabolic-associated fatty liver disease in Mexico and development of a screening tool: the MAFLD-S score","volume":"1","author":"Ruiz-Manriquez","year":"2022","journal-title":"Gastro Hep Adv"},{"issue":"6","key":"10.1016\/j.cld.2023.01.016_bib20","doi-asserted-by":"crossref","first-page":"909","DOI":"10.5604\/01.3001.0010.5282","article-title":"The expression of PNPLA3 polymorphism could be the key for severe liver disease in NAFLD in hispanic population","volume":"16","author":"Mart\u00ednez","year":"2017","journal-title":"Ann Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2023.01.016_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/nu11010045","article-title":"Trends in ultra-processed food purchases from 1984 to 2016 in Mexican households","volume":"11","author":"Marr\u00f3n-Ponce","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.cld.2023.01.016_bib22","doi-asserted-by":"crossref","first-page":"100359","DOI":"10.1016\/j.aohep.2021.100359","article-title":"NAFLD: challenges and opportunities to address the public health problem in Latin America","volume":"24","author":"Arab","year":"2021","journal-title":"Ann Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2023.01.016_bib23","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3390\/nu13061977","article-title":"Beyond the paradigm of weight loss in non-alcoholic fatty liver disease: from pathophysiology to novel dietary approaches","volume":"13","author":"Armandi","year":"2021","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.cld.2023.01.016_bib24","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jhep.2019.05.033","article-title":"Intelligent liver function testing (iLFT): a trial of automated diagnosis and staging of liver disease in primary care","volume":"71","author":"Dillon","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2023.01.016_bib25","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2023.01.016_bib26","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-pathol-012615-044224","article-title":"Nonalcoholic fatty liver disease: pathogenesis and disease spectrum","volume":"11","author":"Hardy","year":"2016","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"5","key":"10.1016\/j.cld.2023.01.016_bib27","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.cld.2023.01.016_bib28","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"An international consensus panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2023.01.016_bib29","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.cgh.2021.07.016","article-title":"Natural history of nonalcoholic fatty liver disease with normal body mass index: a population-based study","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2023.01.016_bib30","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/gutjnl-2020-322564","article-title":"Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?","volume":"71","author":"Younes","year":"2022","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cld.2023.01.016_bib31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1055\/s-0038-1677517","article-title":"NASH in lean individuals","volume":"39","author":"Younes","year":"2019","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cld.2023.01.016_bib32","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2022.06.023","article-title":"AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review","author":"Long","year":"2022","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2023.01.016_bib33","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"Bianco","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2023.01.016_bib34","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1053\/j.gastro.2017.01.015","article-title":"Metabolomic identification of subtypes of nonalcoholic steatohepatitis","volume":"152","author":"Alonso","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2023.01.016_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/hep.32427","article-title":"Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles","author":"Mart\u00ednez-Arranz","year":"2022","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2023.01.016_bib36","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2021.10.013","article-title":"Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease","volume":"76","author":"Luukkonen","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2023.01.016_bib37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2023.01.016_bib38","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jhep.2019.11.024","article-title":"A\u00a0randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis","volume":"72","author":"Harrison","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2023.01.016_bib39","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2023.01.016_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.07.004","article-title":"Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design","author":"Allen","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.01.016_bib41","author":"EMA"},{"issue":"3","key":"10.1016\/j.cld.2023.01.016_bib43","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/j.gastro.2021.10.051","article-title":"Expert panel review to compare FDA and EMA guidance on drug development and endpoints in nonalcoholic steatohepatitis","volume":"162","author":"Loomba","year":"2022","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2023.01.016_bib44","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41591-021-01652-8","article-title":"Non-invasive biomarkers of nonalcoholic steatohepatitis: the FNIH NIMBLE project","volume":"28","author":"Sanyal","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.cld.2023.01.016_bib45","article-title":"Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: diagnostic and mechanistic relevance","volume":"4","author":"Johnson","year":"2021","journal-title":"JHEP reports Innov Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2023.01.016_bib46","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study","volume":"76","author":"Rinella","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2023.01.016_bib47","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jhep.2021.12.031","article-title":"Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events","volume":"76","author":"Boursier","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2023.01.016_bib48","doi-asserted-by":"crossref","first-page":"453","DOI":"10.14309\/ajg.0000000000001606","article-title":"Fibrosis-4 index can independently predict major adverse cardiovascular events in nonalcoholic fatty liver disease","volume":"117","author":"Vieira Barbosa","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2023.01.016_bib49","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/gutjnl-2020-321964","article-title":"NAFLD between genes and environment: what drives fibrogenesis?","volume":"70","author":"Armandi","year":"2021","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.cld.2023.01.016_bib50","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: revisited after a decade","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2023.01.016_bib51","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.cgh.2018.06.011","article-title":"Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis","volume":"17","author":"Han","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2023.01.016_bib52","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11901-020-00505-1","article-title":"Accounting for the placebo effect and optimizing outcomes in clinical trials of nonalcoholic steatohepatitis (NASH)","volume":"19","author":"Noureddin","year":"2020","journal-title":"Curr Hepatol Reports"},{"issue":"4","key":"10.1016\/j.cld.2023.01.016_bib53","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2023.01.016_bib54","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/jgh.15363","article-title":"Relationship between dietary patterns and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"36","author":"Hassani Zadeh","year":"2021","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"17","key":"10.1016\/j.cld.2023.01.016_bib55","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.3390\/ijerph16173011","article-title":"Diet and non-alcoholic fatty liver disease: the mediterranean way","volume":"16","author":"Abenavoli","year":"2019","journal-title":"Int J Environ Res Public Health"},{"issue":"S1","key":"10.1016\/j.cld.2023.01.016_bib56","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/liv.14360","article-title":"The role of nutrition in non-alcoholic fatty liver disease: pathophysiology and management","volume":"40","author":"Bern\u00e1","year":"2020","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.cld.2023.01.016_bib57","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jhep.2017.10.005","article-title":"The nutritional geometry of liver disease including non-alcoholic fatty liver disease","volume":"68","author":"Simpson","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2023.01.016_bib58","doi-asserted-by":"crossref","first-page":"100322","DOI":"10.1016\/j.jhepr.2021.100322","article-title":"Non-alcoholic fatty liver disease: a patient guideline","volume":"3","author":"Francque","year":"2021","journal-title":"JHEP Reports Innov Hepatol"},{"issue":"11\u201312","key":"10.1016\/j.cld.2023.01.016_bib59","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/j.1365-2036.2009.04141.x","article-title":"Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults: the Rancho Bernardo Study","volume":"30","author":"Loomba","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.cld.2023.01.016_bib60","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"51","author":"Ascha","year":"2010","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2023.01.016_bib61","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jhep.2014.11.025","article-title":"Roles of alcohol consumption in fatty liver: a longitudinal study","volume":"62","author":"Moriya","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.01.016_bib62","doi-asserted-by":"crossref","first-page":"154439","DOI":"10.1016\/j.metabol.2020.154439","article-title":"Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus","volume":"115","author":"Blomdahl","year":"2021","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.cld.2023.01.016_bib63","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"Electronic address: easloffice@easloffice.eu, European association for the study of diabetes (EASD), European association for the study of obesity (EASO). EASL\u2013EASD\u2013EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2023.01.016_bib64","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.gastrohep.2017.12.003","article-title":"Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline","volume":"41","author":"Aller","year":"2018","journal-title":"Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2023.01.016_bib65","doi-asserted-by":"crossref","first-page":"e0265153","DOI":"10.1371\/journal.pone.0265153","article-title":"Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life","volume":"17","author":"Carol","year":"2022","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.cld.2023.01.016_bib66","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/cld.571","article-title":"Biomarkers for monitoring alcohol use","volume":"8","author":"Cabezas","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cld.2023.01.016_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.04.040","article-title":"Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease","author":"Staufer","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2023.01.016_bib68","doi-asserted-by":"crossref","first-page":"e14595","DOI":"10.1111\/ctr.14595","article-title":"Availability of PEth testing is associated with reduced eligibility for liver transplant among patients with alcohol-related liver disease","volume":"36","author":"Selim","year":"2022","journal-title":"Clin Transplant"},{"issue":"6","key":"10.1016\/j.cld.2023.01.016_bib69","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2023.01.016_bib70","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.cld.2023.01.016_bib71","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A\u00a0global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.cld.2023.01.016_bib72","doi-asserted-by":"crossref","first-page":"e013927","DOI":"10.1136\/bmjopen-2016-013927","article-title":"Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Liao","year":"2017","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.cld.2023.01.016_bib73","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.cld.2023.01.016_bib74","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2023.01.016_bib75","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2023.01.016_bib76","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/nyas.13441","article-title":"Endoluminal weight loss and metabolic therapies: current and future techniques","volume":"1411","author":"Hill","year":"2018","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.1016\/j.cld.2023.01.016_bib77","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1055\/a-1224-7231","article-title":"Endoscopic sleeve gastroplasty, laparoscopic sleeve gastrectomy, and laparoscopic greater curve plication: do they differ at 2 years?","volume":"53","author":"Lopez-Nava","year":"2021","journal-title":"Endoscopy"},{"issue":"3","key":"10.1016\/j.cld.2023.01.016_bib78","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.gie.2015.03.1964","article-title":"ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies","volume":"82","author":"Abu Dayyeh","year":"2015","journal-title":"Gastrointest Endosc"},{"issue":"1","key":"10.1016\/j.cld.2023.01.016_bib79","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cgh.2020.04.068","article-title":"Intragastric balloon placement induces significant metabolic and histologic improvement in patients with nonalcoholic steatohepatitis","volume":"19","author":"Bazerbachi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2023.01.016_bib80","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/ijo.2016.229","article-title":"Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial","volume":"41","author":"Courcoulas","year":"2017","journal-title":"Int J Obes"},{"issue":"2","key":"10.1016\/j.cld.2023.01.016_bib81","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.soard.2019.11.012","article-title":"Safety and efficacy of endoscopic sleeve gastroplasty worldwide for treatment of obesity: a systematic review and meta-analysis","volume":"16","author":"Singh","year":"2020","journal-title":"Surg Obes Relat Dis"},{"issue":"1","key":"10.1016\/j.cld.2023.01.016_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-021-05695-7","article-title":"Efficacy and safety of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy in obese subjects with Non-Alcoholic SteatoHepatitis (NASH): study protocol for a randomized controlled trial (TESLA-NASH study)","volume":"22","author":"Lav\u00edn-Alconero","year":"2021","journal-title":"Trials"},{"issue":"7384","key":"10.1016\/j.cld.2023.01.016_bib83","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature10809","article-title":"Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity","volume":"482","author":"Henao-Mejia","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.cld.2023.01.016_bib84","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41598-017-01751-y","article-title":"Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.cld.2023.01.016_bib85","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1136\/gutjnl-2012-303816","article-title":"Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice","volume":"62","author":"Le Roy","year":"2013","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.cld.2023.01.016_bib86","first-page":"1369","article-title":"A\u00a0role for gut microbiome fermentative pathways in fatty liver disease progression","volume":"9","author":"Iruzubieta","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"7","key":"10.1016\/j.cld.2023.01.016_bib87","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.14309\/ajg.0000000000000661","article-title":"Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial","volume":"115","author":"Craven","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.cld.2023.01.016_bib88","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep4.1601","article-title":"Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis","volume":"4","author":"Witjes","year":"2020","journal-title":"Hepatol Commun"},{"issue":"6","key":"10.1016\/j.cld.2023.01.016_bib89","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jhep.2021.12.003","article-title":"Promises of microbiome-based therapies","volume":"76","author":"Bajaj","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"7783","key":"10.1016\/j.cld.2023.01.016_bib90","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41586-019-1742-x","article-title":"Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease","volume":"575","author":"Duan","year":"2019","journal-title":"Nature"},{"issue":"7919","key":"10.1016\/j.cld.2023.01.016_bib91","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/d41586-022-01959-7","article-title":"How gut bacteria could boost cancer treatments","volume":"607","author":"Erdmann","year":"2022","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.cld.2023.01.016_bib92","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/13543784.2021.1879792","article-title":"A\u00a0perspective on RNA interference-based therapeutics for metabolic liver diseases","volume":"30","author":"Alkhouri","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"issue":"12","key":"10.1016\/j.cld.2023.01.016_bib93","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.135348","article-title":"Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease","volume":"5","author":"Wooddell","year":"2020","journal-title":"JCI Insight"},{"issue":"24","key":"10.1016\/j.cld.2023.01.016_bib94","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2023.01.016_bib95","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.molmet.2019.01.013","article-title":"Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice","volume":"22","author":"Lind\u00e9n","year":"2019","journal-title":"Mol Metab"},{"issue":"3","key":"10.1016\/j.cld.2023.01.016_bib96","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jcmgh.2018.12.004","article-title":"Targeted delivery of Stk25 antisense oligonucleotides to hepatocytes protects mice against nonalcoholic fatty liver disease","volume":"7","author":"Cansby","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.01.016_bib97","author":"Telehealth Basics - ATA"},{"issue":"8","key":"10.1016\/j.cld.2023.01.016_bib98","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/jvh.12885","article-title":"Impact of electronic reminder systems on hepatitis C screening in primary care","volume":"25","author":"MacLean","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cld.2023.01.016_bib99","doi-asserted-by":"crossref","first-page":"103031","DOI":"10.1016\/j.drugpo.2020.103031","article-title":"Telemedicine efficiently improves access to hepatitis C management to achieve HCV elimination in the penitentiary setting","volume":"88","author":"Cuadrado","year":"2021","journal-title":"Int J Drug Policy"},{"issue":"50","key":"10.1016\/j.cld.2023.01.016_bib100","doi-asserted-by":"crossref","first-page":"E28027","DOI":"10.1097\/MD.0000000000028027","article-title":"The application effect of internet technology on managing patients with hypertension in a medical center: a prospective case-control study","volume":"100","author":"Yin","year":"2021","journal-title":"Medicine (Baltim)"},{"issue":"9","key":"10.1016\/j.cld.2023.01.016_bib101","doi-asserted-by":"crossref","first-page":"E341","DOI":"10.1503\/cmaj.150885","article-title":"Effect of telemedicine on glycated hemoglobin in diabetes: a systematic review and meta-analysis of randomized trials","volume":"189","author":"Faruque","year":"2017","journal-title":"CMAJ (Can Med Assoc J)"},{"issue":"1","key":"10.1016\/j.cld.2023.01.016_bib102","doi-asserted-by":"crossref","first-page":"e20491","DOI":"10.2196\/20491","article-title":"Digital intervention with lifestyle coach support to target dietary and physical activity behaviors of adults with nonalcoholic fatty liver disease: systematic development process of VITALISE using intervention mapping","volume":"23","author":"Hallsworth","year":"2021","journal-title":"J\u00a0Med Internet Res"},{"issue":"4","key":"10.1016\/j.cld.2023.01.016_bib103","doi-asserted-by":"crossref","first-page":"e14802","DOI":"10.2196\/14802","article-title":"Lifestyle intervention enabled by mobile technology on weight loss in patients with nonalcoholic fatty liver disease: randomized controlled trial","volume":"8","author":"Lim","year":"2020","journal-title":"JMIR mHealth uHealth"},{"key":"10.1016\/j.cld.2023.01.016_bib104","doi-asserted-by":"crossref","unstructured":"Schattenberg J.M., Allen A.M., Jarvis H., et al., A multistakeholder approach to innovations in NAFLD care, Commun Med (Lond), 3 (1), 1.","DOI":"10.1038\/s43856-022-00228-y"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:00:27Z","timestamp":1761069627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326123000168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":101,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1089326123000168"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2023.01.016","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research Priorities for Precision Medicine in NAFLD","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2023.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}